医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Statement from Dr. Reddy’s Regarding the Receipt of Temporary Restraining Order (TRO) for Esomeprazole Capsules

2015年11月10日 PM08:18
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) in a statement issued today said that it has been made aware of an order passed by the District Court of Delaware, USA, granting a Temporary Restraining Order (TRO) with immediate effect on sales, delivery, transfer, or other disposition of its generic esomeprazole product in the US market.

The order came about as a result of a motion moved by Astra Zeneca objecting to the usage of the colour Purple in the said generic product.

The order has been passed pending further hearing or trial. The Court has asked the parties to propose a next course of action and submit the same to the court. The court shall conduct a telephonic status conference on Thursday, November 12, 2015.

The Company is complying with the order of the Court and simultaneously evaluating all possible options to resolve the matter at the earliest.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may,” “will,” “should,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151110005871/en/

CONTACT

Dr. Reddy’s Laboratories Ltd.
INVESTOR RELATIONS
KEDAR
UPADHYE, +91-40-66834297
kedaru@drreddys.com
or
MEDIA
RELATIONS

CALVIN PRINTER, +91-40-49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定
  • オクタファルマ、薬物動態に基づくNuwiq®個別化予防療法(NuPreviq法)に関する新しい臨床データの発表により、血友病A患者への強いコミットメントを浮き彫りに
  • ハーバライフ・ニュートリション、健康的でアクティブな生活を促すリーダーとなれるよう、東南アジアのメンバーを鼓舞